RxDoctor Payments Data

Nancy Rosales, MD

Neurology · Winston Salem, NCNPI 1114246717

Payments from drug & device makers

$825in general payments, 2019–2025

Across 28 payments — averaging $29.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$223
  • Biogen$168
  • AstraZeneca$124
  • Genentech, Inc.$88
  • Vanda Pharmaceuticals Inc.$52
  • TG Therapeutics, Inc.$41
  • plus $129 from 6 others

What the payments were for

  • Food & beverage$47958%
  • Education$34642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$825 in reported general payments places this provider in the 45th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$32,385
Medicare patients
155
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate26$216,697
TecfideraDimethyl Fumarate11$102,227
Emgality PenGalcanezumab-Gnlm26$23,887
Dalfampridine ErDalfampridine44$16,565
Levetiracetam149$3,256
Gabapentin158$2,755
Dimethyl Fumarate13$1,923
Lacosamide19$1,566
Memantine Hcl81$1,558
Duloxetine Hcl47$1,131
Baclofen92$934
Carbidopa-LevodopaCarbidopa/Levodopa28$875
Donepezil Hcl122$848
Amitriptyline Hcl78$743
Pregabalin20$577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Tecfidera$168$318,92437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 566 neurology providers in North Carolina.

Other neurology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →